Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial

Table 4 Incontinence Quality of Life questionnaire: subscale scores.

			I-QOL Avoidance and Limiting Behavior Subscale Score				I-QOL Psychological Impact Subscale Score				I-QOL Social Embarrassment Subscale Score
Treatment group (N)†	Time point	n‡	Mean I-QOL	Mean change in I-QOL from baseline§	95% CI for treatment difference in I-QOL¶	P	Mean I-QOL	Mean change in I-QOL from baseline§	95% CI for treatment difference in I-QOL¶	P	Mean I-QOL	Mean change in I-QOL from baseline§	95% CI for treatment difference in IQOL¶	P
Placebo (61)	Baseline	59	62.34		(-5.26,6.46)		64.22		(-3.73,7.89)		54.07		(-7.37,6.82)
	Endpoint		75.16	12.82			76.22	12.01			70.59	16.53
Duloxetine (60)	Baseline	52	63.28				66.72				54.33
	Endpoint		75.96	12.68		.839	79.65	12.93		.480	70.77	16.44		.940

†N = number randomized.
‡n = number with diary data available for specified analysis.
^§Baseline is the last nonmissing visit score on or before randomization.
¶95% CI for treatment difference.
Abbreviations: CI = confidence interval; I-QOL = Incontinence Quality of Life questionnaire

ISSN: 1471-2490